AstraZeneca

AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Company Growth (employees)
Type
Public
HQ
Cambridge, GB
Founded
1999
Size (employees)
59,700 (est)
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB

Key People at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

CFO
Herren Wu

Herren Wu

CTO
Bahija Jallal

Bahija Jallal

Executive Vice President
Menelas Pangalos

Menelas Pangalos

Executive Vice President
Mark Mallon

Mark Mallon

Executive Vice President
Jeff Pott

Jeff Pott

General Counsel
Katarina Ageborg

Katarina Ageborg

Chief Compliance Officer
Caroline Hempstead

Caroline Hempstead

Executive Vice President, Human Resources and Corporate Affairs (interim)
Pam Cheng

Pam Cheng

Executive Vice-President
Fiona Cicconi

Fiona Cicconi

Executive Vice-President, Human Resources

AstraZeneca Office Locations

AstraZeneca has offices in Cambridge, London, Bangalore, Hong Kong and in 166 other locations
Wedel, DE
Wedel, Tinsdaler Weg 183
Wilmington, US
1800 Concord Pike, P.O. Box 15437
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Show all (171)

AstraZeneca Data and Metrics

AstraZeneca Financial Metrics

AstraZeneca's revenue was reported to be $21.3 b in FY, 2016 which is a 10% decrease from the previous period.
USD

Revenue (FY, 2016)

21.3 b

Revenue growth (FY, 2015 - FY, 2016), %

(10%)

Gross profit (FY, 2016)

17.2 b

Gross profit margin (FY, 2016), %

81%

Net income (FY, 2016)

3.4 b

Market capitalization (22-Sep-2017)

86 b

Closing share price (22-Sep-2017)

32.8

Cash (31-Dec-2016)

3.9 b
AstraZeneca's current market capitalization is $86 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

25.7 b26.1 b23.6 b21.3 b

Revenue growth, %

1%(9%)(10%)

Cost of goods sold

5.3 b5.8 b4.6 b4.1 b

Gross profit

20.5 b20.3 b19 b17.2 b
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

6.1 b4.7 b4.6 b3.9 b

Accounts Receivable

3.6 b3.5 b3.4 b2 b

Current Assets

13.2 b12.2 b11.7 b10.1 b

PP&E

6.4 b7 b7.2 b8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

7.4 b7.1 b3.3 b4.1 b

Cash From Financing Activities

(2 b)(2 b)649.3 m1.7 b

Income Taxes Paid

(457.7 m)(8.1 m)(179.7 m)(113.1 m)
Y, 2016

Financial Leverage

4.2 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase I Trials

33244441

Countries

100100100100

Phase II Trials

27113336

Projects in R&D Pipeline

99133146132
Show all operating metrics

AstraZeneca Market Value History

AstraZeneca Revenue Breakdown

AstraZeneca Median Salaries

Source: 105 public H-1B filings from AstraZeneca

Traffic Overview of AstraZeneca

AstraZeneca Online and Social Media Presence

AstraZeneca News and Updates

Tardive Dyskinesia (TD) Treatment Market Analysis by Size & Share by 2024

The market for the tardive dyskinesia treatment will grow significantly in the coming years. The key factor that is driving the tardive dyskinesia treatment market is the increasing number of people that are suffering from the neurological disorders. Posted via Industry Today. Follow us on Twitter @…

Chronic Lung Diseases Treatment Market to witness steady increase by 2024

The key factor that will fuel the chronic lung diseases treatment market in the future years is the increasing cases of chronic COPD and asthma. Posted via Industry Today. Follow us on Twitter @IndustryToday

Chronic Respiratory Diseases Treatment Market: Top Industry Trends & Segments Forecast 2016-2024

The major factors that will contribute to the growth of the chronic respiratory diseases treatment market in the coming years are the favorable initiatives taken by the government, good reimbursement policies, increasing number of cases, and the rise in the number of people addicted to smoking. Pos…

Blood Preparation Market will achieve 4.4% growth to surpass USD 64.3 billion by 2024

Key industry players in Blood Preparation Market are focusing on R&D to develop cost effective novel technologies to consolidate their market position. Posted via Industry Today. Follow us on Twitter @IndustryToday

Genome Editing Market will grow at 14% CAGR to exceed $7.5 billion by 2024

U.S. Genome Editing Market share was USD 518.5 million in 2015 and will continue to grow at healthy CAGR in coming years, due to the robust growth trend manifested by pharmaceutical industries & adoption of advanced technologies like CRISPR to treat chronic hereditary disorders. Posted via Indu…

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

Big Pharma expanded in emerging markets 6.1% last quarter, the biggest jump in more than two years, but GlaxoSmithKline and Eli Lilly didn't reap as much growth as their peers—and all of them may face rising threats ahead.
Show more

AstraZeneca Company Life and Culture

You may also be interested in